Carboplatin and hypofractionated accelerated radiotherapy: A dose escalation study of an outpatient chemoradiation schedule for squamous cell carcinoma of the head and neck

被引:18
作者
Madhava, K
Hartley, A [1 ]
Wake, M
Watkinson, JC
Glaholm, J
机构
[1] Queen Elizabeth Hosp, Ctr Canc, Birmingham B15 2TH, W Midlands, England
[2] Birmingham Heartlands Hosp, ENT Dept, Birmingham B9 5ST, W Midlands, England
关键词
carboplatin; chemoradiation; head and neck cancer; hypofractionation;
D O I
10.1016/j.clon.2005.08.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To examine the feasibility and determine the maximum tolerated dose Of Outpatient carboplatin given with synchronous hypofractionated accelerated radiotherapy for squamous cell carcinoma of the head and neck (SCCHN). Materials and methods: Patients with stages II-IV SCCHN and unresected primary tumour were treated with synchronous carboplatin given in an outpatient setting on day 1 and day 21 in cohorts of three to six patients with incremental area under curve (AUC) factors commencing at 3.5. Grade 3 mucositis persisting for 4 weeks in two patients in a cohort was considered dose limiting. Results: A total of 19 patients were enrolled and assessable for toxicity. All 19 patients completed 55 Gy of radiotherapy and were assessable for response. Grade 3 mucositis lasting 4 weeks or more was seen in three patients, two of them received ALIC 5 carboplatin. A complete response was seen in 16 patients, with a further patient having a partial response, giving a response rate of 89%. with a median follow-up of 24 months (range 11-30 months), 13 patients were alive with no evidence of recurrent disease. Local recurrence had occurred in four patients with distant spread in three patients. Conclusion: Carboplatin with concurrent hypofractionated accelerated radiotherapy is feasible for patients with advanced SCCHN and good performance status. The recommended phase II dose of carboplatin given in week 1 and week 4 with 55 Gy in 20 fractions is AUC 4.5.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 19 条
[1]   Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer [J].
Brizel, DM ;
Albers, ME ;
Fisher, SR ;
Scher, RL ;
Richtsmeier, WJ ;
Hars, V ;
George, SL ;
Huang, AT ;
Prosnitz, LR .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (25) :1798-1804
[2]   Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis [J].
Browman, GP ;
Hodson, DI ;
Mackenzie, RJ ;
Bestic, N ;
Zuraw, L .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2001, 23 (07) :579-589
[3]   Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma [J].
Calais, G ;
Alfonsi, M ;
Bardet, E ;
Sire, C ;
Germain, T ;
Bergerot, P ;
Rhein, B ;
Tortochaux, J ;
Oudinot, P ;
Bertrand, P .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (24) :2081-2086
[4]   Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? [J].
Denham, JW ;
Peters, LJ ;
Johansen, J ;
Poulsen, M ;
Lamb, DS ;
Hindley, A ;
O'Brien, PC ;
Spry, NA ;
Penniment, M ;
Krawitz, H ;
Williamson, S ;
Bear, J ;
Tripcony, L .
RADIOTHERAPY AND ONCOLOGY, 1999, 52 (02) :157-164
[5]   A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003 [J].
Fu, KK ;
Pajak, TF ;
Trotti, A ;
Jones, CU ;
Spencer, SA ;
Phillips, TL ;
Garden, AS ;
Ridge, JA ;
Cooper, JS ;
Ang, KK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (01) :7-16
[6]  
Haselow RE, 1990, HEAD NECK CANC, P279
[7]  
Henk J M, 1997, Clin Oncol (R Coll Radiol), V9, P308, DOI 10.1016/S0936-6555(05)80064-0
[8]   Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial [J].
Jeremic, B ;
Shibamoto, Y ;
Stanisavljevic, B ;
Milojevic, L ;
Milicic, B ;
Nikolic, N .
RADIOTHERAPY AND ONCOLOGY, 1997, 43 (01) :29-37
[9]  
Lavertu P, 1997, HEAD NECK-J SCI SPEC, V19, P559, DOI 10.1002/(SICI)1097-0347(199710)19:7<559::AID-HED1>3.0.CO
[10]  
2-6